Information for "Anti-restenotic efficacy of SES is non-superior to PES in patients with SES-restenosis: Results of the ISAR-DESIRE 2 Trial"
Jump to navigation
Jump to search
Basic information
| Display title | Anti-restenotic efficacy of SES is non-superior to PES in patients with SES-restenosis: Results of the ISAR-DESIRE 2 Trial |
| Default sort key | Anti-restenotic efficacy of SES is non-superior to PES in patients with SES-restenosis: Results of the ISAR-DESIRE 2 Trial |
| Page length (in bytes) | 6,114 |
| Namespace ID | 0 |
| Page ID | 178725 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Number of subpages of this page | 0 (0 redirects; 0 non-redirects) |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Apalmer (talk | contribs) |
| Date of page creation | 17:41, 25 September 2009 |
| Latest editor | Apalmer (talk | contribs) |
| Date of latest edit | 18:35, 25 September 2009 |
| Total number of edits | 11 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 30 days) | 0 |
| Recent number of distinct authors | 0 |
Page properties
| Magic word (1) |
|